STOCKHOLM, Sweden, Jan 09, 2017 /PRNewswire/ --
Medivir AB (Nasdaq Stockholm: MVIR) is conducting an analyst and investor conference call/webcast today, 9th January 2017, at 15.00 CET,to present further financial aspects of the acquired oncology programs from TetraLogic Pharmaceuticals Corporation, including the clinical stage compounds remetinostat and birinapant.
Niklas Prager CEO, Ola Burmark CFO and Richard Bethell CSO will be presenting and will be available for questions.
To join the conference call, please dial:
Sweden +46 (0)8 566 426 62
Europe +44(0)20 300 898 02
USA +1 855 753 22 35
The webcast can be accessed on the website: www.medivir.com
For further information, please contact:
CEO and President Medivir AB,
CSO Medivir AB,
Mobile +46 (0)72-704-3211
CFO Medivir AB,
Mobile: +46 (0) 725-480-580
Medivir is a research based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir's class B share is listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivir---invitation-to-conference-call-and-webcast-300387551.html